[RADIATOR] <AddressPool> behaves how?

[Jens Neu]

Dear All,

I'm evaluating Radiator for our setup, and I've stumpled on this 
behaviour. (Part of) my setup is as follows:


<AddressAllocator SQL>
        Identifier myidentifier
        Identifier mypools
        DBSource        dbi:Oracle:db.example.com;service_name=sid
        DBUsername      radiator
        DBAuth          radiator

        <AddressPool pool1>
                Subnetmask      255.255.255.0
                Range   10.0.196.1 10.0.196.254 
        </AddressPool>

        <AddressPool pool2>
                Subnetmask      255.255.254.0
                Range   172.20.0.1 172.20.1.254
        </AddressPool>
</AddressAllocator>

the first Pool "pool1" behaves as expected; entries for 10.0.196.1 till 
10.0.196.254 are created,

select count(*) from RADPOOL where POOL='verizon_dial_access_pool

checks out as 254, pieceofcake.

but the second "pool2" creates entries for 172.20.0.0 as well as 
172.20.1.255 in my RADPOOL table. I mean I could manually delete these two 
rows after initial setup, but I would like to understand whats happening 
here...

best regards from Berlin
Jens Neu

Health Services Network Administration

Phone: +49 (0) 30 68905-2412
Mail: jens.neu at biotronik.de


www.biotronik.com

BIOTRONIK SE & Co. KG
Woermannkehre 1, 12359 Berlin, Germany
Sitz der Gesellschaft: Berlin, Registergericht: Berlin HRA 6501

Vertreten durch ihre Komplementärin:
BIOTRONIK MT SE
Sitz der Gesellschaft: Berlin, Registergericht: Berlin HRB 118866 B
Geschäftsführende Direktoren: Christoph Böhmer, Dr. Werner Braun, Dr. 
Lothar Krings, Dr. Torsten Wolf

BIOTRONIK - A global manufacturer of advanced Cardiac Rhythm Management 
systems and Vascular Intervention devices. Quality, innovation, and 
reliability define BIOTRONIK and our growing success. We are innovators of 
technologies like the first wireless remote monitoring system - Home 
Monitoring®, Closed Loop Stimulation and coveted lead solutions as well as 
state-of-the-art stents, balloons and guide wires for coronary and 
peripheral indications. We highly invest in the development of drug 
eluting devices and are leading the industry with our drug eluting 
absorbable metal scaffold program.

This e-mail and the information it contains including attachments are 
confidential and meant only for use by the intended recipient(s); 
disclosure or copying is strictly prohibited. If you are not addressed, 
but in the possession of this e-mail, please notify the sender immediately 
and delete the document.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: http://www.open.com.au/pipermail/radiator/attachments/20120502/79174945/attachment.html